Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN 5 versus AMINOSYN II 15 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN 5 versus AMINOSYN II 15 IN PLASTIC CONTAINER.
AMINOSYN 5% vs AMINOSYN II 15% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosyn 5% provides essential and nonessential amino acids for protein synthesis, maintaining nitrogen balance, and supporting tissue repair in patients unable to tolerate oral intake.
Provides essential amino acids for protein synthesis, serving as substrates for nitrogen balance and tissue repair.
Intravenous infusion; 500 mL of 5% solution (25 g protein equivalent) per day, typically at a rate not exceeding 100 mL/hour. Dosage individualized based on protein requirements and metabolic status.
Intravenous infusion: 1.0 to 2.0 g amino acids/kg/day, maximum 125 mL/hour (3 g amino acids/kg/day).
None Documented
None Documented
Not applicable as a drug; amino acids have rapid turnover with half-lives varying from minutes to hours depending on the individual amino acid.
Amino acids: rapid clearance, half-life 0.5-2 hours depending on individual and metabolic state. Clinical context: continuous infusion maintains steady state.
Amino acids are metabolized; nitrogen is excreted renally as urea (80-90%) and in feces (5-10%).
Renal: amino acids are filtered and reabsorbed; excess nitrogen is excreted as urea in urine. <5% fecal.
Category C
Category C
Amino Acid Solution
Amino Acid Solution